A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Abroad (travel likely)RecruitingPHASE3
Conditions
Ovarian Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
GSK Investigational Site, Randwick, New South Wales, Australia
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Katherine Francis)GSK Investigational Site, Montreal, Quebec, Canada
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Diane Provencher)GSK Investigational Site, Montreal, Quebec, Canada
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Lucy Gilbert)GSK Investigational Site, Hyōgo, Japan
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Kasumi Yamamoto)GSK Investigational Site, Osaka, Japan
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Satoe Fujiwara)